 SAN DIEGO, Sept. 02, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation Nasdaq: ADMP today announced the initiation of patient dosing in the Phase 23 clinical trial for Tempol, an oral antiviral product candidate, in adult patients with confirmed COVID-19 infection. In preclinical studies, Tempol has been shown to have antiviral, anti-inflammatory and antioxidant activity. The trial is designed to enroll 248 patients. 